Actively Recruiting
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Led by Shanghai Junshi Bioscience Co., Ltd. · Updated on 2026-02-06
66
Participants Needed
18
Research Sites
49 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multiple-arm, open phase II clinical trial evaluating the safety, tolerability,and preliminary efficacy of JS207 in NSCLC after progression following Platinum-based chemotherapy and immunotherapy.
CONDITIONS
Official Title
Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed locally advanced (stage IIIB/IIIC) NSCLC not suitable for radical surgery or radiochemotherapy, or metastatic or recurrent NSCLC
- Unresectable locally advanced, metastatic, or recurrent NSCLC with disease progression after first-line PD-1/PD-L1 inhibitors combined with platinum-based doublet chemotherapy (excluding docetaxel), or after sequential first- and second-line PD-1/PD-L1 inhibitors followed by platinum-based doublet chemotherapy (excluding docetaxel)
- At least one measurable lesion according to RECIST v1.1
- Age between 18 and 75 years
You will not qualify if you...
- Presence of combined neuroendocrine component confirmed by histopathology or cytopathology
- Known sensitizing mutations in EGFR or ALK fusion
- Tumors encircling important blood vessels or with obvious necrosis and air space posing a hemorrhage risk as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 18 locations
1
Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 101100
Actively Recruiting
2
Jilin Cancer Hospital
Jilin, Changchun, China, 130012
Actively Recruiting
3
Hunan Cancer Hospital
Hunan, Changsha, China, 410031
Actively Recruiting
4
West China Hospital, Sichuan University
Sichuan, Chengdu, China, 610044
Actively Recruiting
5
Second Affiliated Hospital, PLA Academy of Military Medical Sciences
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
6
Army Medical Center, PLA
Chongqing, Chongqing Municipality, China, 400042
Actively Recruiting
7
The First Affiliated Hospital of Guangzhou Medical University
Guangdong, Guangzhou, China, 510120
Actively Recruiting
8
Harbin Medical University Cancer Hospital
Heilongjiang, Harbin, China, 150081
Actively Recruiting
9
Anyang Tumor Hospital
Anyang, Henan, China, 455000
Actively Recruiting
10
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 471003
Actively Recruiting
11
The First Affiliated Hospital of Xinxiang Medical University
Xinxiang, Henan, China, 453100
Actively Recruiting
12
The First People's Hospital of Changde
Changde, Hunan, China, 415003
Actively Recruiting
13
The First Affiliated Hospital of Nanchang University
Jiangxi, Nanchang, China, 330000
Actively Recruiting
14
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
15
The Third People's Hospital of Datong
Datong, Shanxi, China, 037008
Actively Recruiting
16
Yibin Second People's Hospital
Yibin, Sichuan, China, 644000
Actively Recruiting
17
Affiliated Tumor Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China, 830011
Actively Recruiting
18
Shanghai Pulmonary Hospital
Shanghai, China, 200433
Not Yet Recruiting
Research Team
X
Xiaojun Wang, Master
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here